MCE 國際站：Sacituzumab govitecan
CAS：1491917-83-9
品牌：MedChemExpress (MCE)
存儲條件：Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性：Sacituzumab govitecan (IMMU-132) 是一種抗體-藥物偶聯物 (ADC)，靶向 Trop-2 以遞送 SN-38。 Sacituzumab govitecan 具有抗癌活性[1]。 體內： Sacituzumab govitecan (IMMU-132)（17.5 mg/kg；每周兩次，持續 4 周）對攜帶人胃癌異種移植物的小鼠產生顯著的抗腫瘤作用[1]。
Magnolol | Bezafibrate | Sonidegib | Prednisolone | Lotiglipron | D-α-Hydroxyglutaric acid (disodium) | GSK-J1 | NAT | Formoterol fumarate | Raloxifene (hydrochloride)研究領域：Antibody-drug Conjugate/ADC Related
作用靶點：Antibody-Drug Conjugates (ADCs)
熱門產品線：重組蛋白 | 化合物庫 | 天然產物 | 熒光染料 | PROTAC | 同位素標記物 | 寡核苷酸
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
參考文獻：
[1]. Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31. [2]. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in Oncotarget. 2020 Mar 10;11(10):942]. Oncotarget. 2015;6(26):22496-22512.
4
立即詢價
您提交后，專屬客服將第一時間為您服務